Q4 2024 Management View CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit ...

The early results have included faster drug discovery, highly optimized supply chains, and greater awareness of consumer demand. For GSK’s Ramakrishnan, who has served as CDTO since 2021 ...

Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...

GSK has pledged to 100% use of renewable across the company by 2025, and an 80% reduction in carbon emissions by 2030 en route to net zero across all its supply chain – including purchased goods ...

GSK, a British drugmaker, recently beat Q4 earnings estimates. The company is our FDI of the Month January 2025.

Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline. It came as the boss of the London-listed firm cheered an “excellent ...

X-ELIO, a global leader in renewable energy, has signed a multi-buyer Power Purchase Agreement (PPA) with an Energize program cohort. This initiative enables four companies to purchase 245 GWh of ...

Chief Financial Officer Julie Brown noted, "Core operating margin improved to 29.2%, up 130 basis points year-on-year," driven by specialty medicines and supply chain efficiencies. GSK expects ...